Core Viewpoint - Yiling Pharmaceutical is accelerating its international expansion, particularly in the anti-aging product sector, as evidenced by the positive reception from Brazilian media executives who are eager to introduce these products to the Brazilian market [1] Group 1: Company Strategy and Innovation - Yiling Pharmaceutical adheres to the principle of "inheritance and innovation" and employs a five-in-one innovative operational model that integrates theory, clinical practice, research, industry, and education, creating a virtuous cycle for sustainable development [3] - The company has established over 60 medicinal herb planting bases across more than 20 provinces in China to ensure high-quality raw materials, adhering to strict planting standards and management systems [5] Group 2: Quality Control and Research - Yiling Pharmaceutical's production facilities have passed international certifications, including those from the US and EU, and have implemented a comprehensive quality management system to ensure the safety and efficacy of its products [5] - The research team collaborates with top international medical research institutions, conducting high-standard evidence-based medical studies and publishing over 300 SCI papers, which validate the efficacy and safety of traditional Chinese medicine [5] Group 3: Brand Development and Market Penetration - The company has developed a systematic theory of "Luo Disease," which has garnered significant attention and multiple national awards, enhancing the brand's credibility and recognition in the international market [6] - Yiling Pharmaceutical has launched 17 patented traditional Chinese medicine products across various clinical fields, including cardiovascular, respiratory, endocrine, oncology, and aging, with a presence in over 50 countries and regions worldwide [7]

证券代码：002603 证券简称：以岭药业 公告编号：2025-037 石家庄以岭药业股份有限公司 2025 年第一次临时股东大会决议公告 （2）网络投票时间：2025 年 9 月 15 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 9 月 15 日上午 9:15—9:25，9:30—11:30，下 午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 9 月 15 日 9:15 至 15:00 的任意时间 2、会议地点：石家庄高新区天山大街 238 号以岭健康城会议室 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2025 年 9 月 15 日下午 14:50 3、会议召开方式：现场投票、网络投票相结合 4、会议召集人和主持人：公司董事会。董事长吴相君先生主持会议。 本次会议的召集、召开程序及表决方式符合有关 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于石家庄以岭药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案内容及该等议 案所表述的事实或数据的真实性、准确性和完整性发表意见； 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东资格、 网络投票结果均由相应的证券交易所交易系统和互联网投票系统予以认证； 国枫律股字[2025]A0449 号 致：石家庄以岭药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 ...

Core Viewpoint - The company held an online earnings briefing on September 15, where it addressed investor inquiries regarding product promotion, sales performance, and future strategies [1]. Group 1: Product Focus - The Ba Zi Bu Shen capsules received attention for their effectiveness, but consumers face challenges in understanding the product's target audience, usage methods, and side effects, prompting a call for increased promotional efforts [2]. - The company stated that Ba Zi Bu Shen capsules are developed based on the theory of Qi and are classified as OTC Class A drugs, with multiple studies confirming their positive effects on age-related diseases [2]. Group 2: Financial Performance - For the first half of 2025, the company reported a revenue of 4.04 billion yuan, a year-on-year decrease of 12.26%, while net profit attributable to shareholders rose by 26.03% to 669 million yuan [3]. - The net profit excluding non-recurring items increased by 27.08% to 641 million yuan, and the net cash flow from operating activities surged by 214.97% to 832 million yuan [3]. - The company emphasized that operational quality is improving and plans to leverage its "Seventh Five-Year" strategy to enhance management, R&D, and marketing for stable growth [3]. Group 3: Future Strategies - The company has established a subsidiary, Shanghai Yiling Pharmaceutical, to advance the development of biopharmaceutical products and enhance its competitive edge in this area [3]. - The company is monitoring policies related to the collection of traditional Chinese medicine in Hubei and plans to increase R&D investment to cultivate new products and expand market share [3]. - The year 2025 is identified as a critical year for the "Seventh Five-Year" plan, focusing on technological innovation, results transformation, and industry development to achieve annual operational and profit targets [3].

Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 4.04 billion, a decrease of 12.26% year-on-year [6] - The net profit attributable to shareholders was CNY 669 million, an increase of 26.03% year-on-year [6] - The net profit excluding non-recurring items was CNY 641 million, up 27.08% year-on-year [6] - The net cash flow from operating activities was CNY 832 million, an increase of 214.97% year-on-year, indicating improved operational quality [4][6] Product Development and Research - The Baizi Bujin Capsule is an OTC Class A drug developed based on the theory of Qi and essence, aimed at anti-aging [5] - Research published in the journal Biomedicine & Pharmacotherapy (impact factor 7.42) confirmed that Baizi Bujin Capsule can improve memory and muscle endurance in aging mice, significantly reducing their DNA methylation age [3][5] - Clinical studies led by the Xiyuan Hospital of the China Academy of Chinese Medical Sciences demonstrated the capsule's effectiveness in improving symptoms of aging across various systems, including neurological and cardiovascular [3][5] Strategic Outlook - The company plans to continue its "Seventh Five-Year" strategic plan, focusing on high-quality industry development and enhancing operational management [5][7] - There is an emphasis on increasing research and development output and optimizing the marketing system to achieve steady growth [5][7] - The establishment of a subsidiary, Shanghai Yiling Pharmaceutical, aims to enhance the company's competitiveness in biopharmaceuticals [7][8] Market and Sales Strategy - The company is committed to increasing the promotion of Baizi Bujin Capsule to convert research advantages into sales advantages [8] - The company is monitoring policies related to centralized procurement and will adapt its strategies accordingly [8] - Future focus includes strengthening budget management and operational efficiency to enhance profitability [8]

Group 1 - The "People's Health Star" science popularization initiative aims to enhance public awareness and understanding of health management, particularly focusing on chronic disease prevention and management [1][3]. - The event featured expert-led lectures and practical health management advice, emphasizing the importance of scientific diet, exercise, medication adherence, and regular health monitoring [1][2]. - The initiative is supported by various organizations, including Yiling Pharmaceutical and Guizhou Yipin Pharmaceutical, which aim to create an integrated service model for safe medication, chronic disease management, and health promotion [3]. Group 2 - The event included health screenings such as carotid plaque detection and blood pressure monitoring, providing residents with direct access to health consultations from medical professionals [3][4]. - The initiative will continue to operate through a combination of online and offline activities, engaging numerous cities and health experts to improve chronic disease prevention and enhance the quality of life for patients [3].

Core Viewpoint - The company, Shijiazhuang Yiling Pharmaceutical Co., Ltd., is participating in the 2025 online collective reception day for investors and the collective performance briefing for the first half of 2025, aimed at enhancing interaction with investors [1]. Group 1 - The event will be held online on September 15, 2025, from 15:00 to 17:00 [1]. - Investors can participate through the "Panjing Roadshow" website, WeChat public account, or by downloading the Panjing Roadshow APP [1]. - Key company executives, including the Chairman and General Manager Wu Xiangjun, will address investor concerns regarding company performance, governance, development strategy, operational status, and sustainable development [1].

证券代码：002603 证券简称：以岭药业 公告编号：2025-036 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与本 次互动交流，活动时间为 2025 年 9 月 15 日（周一）15:00-17:00。届时公司董事长、 总经理吴相君，董事、董事会秘书吴瑞，董事、财务负责人李晨光将在线就公司业 绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与投资者 进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 石家庄以岭药业股份有限公司 董事会 2025 年 9 月 11 日 关于参加 2025 年河北辖区上市公司投资者网上集体接待日 暨 2025 年半年报集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，石家庄以岭药业股份有限公司（以下简称 "公司"）将参加由河北省上市公司协会联合深圳市全景网络有限公司举办的"2025 年河北辖区上市公司投资者网上集体接待日暨 2025年半年报集体 ...

Core Points - The 2025 list of the top 100 private enterprises in Hebei Province was released by the Hebei Federation of Industry and Commerce on September 9 [1] - The list includes various sectors, highlighting the diversity and strength of private enterprises in the region [6] Group 1: Top 100 Private Enterprises - The list features companies such as Yuhua Steel Co., Ltd., Tangshan Ganglu Steel Co., Ltd., and Jinko Solar Technology Co., Ltd. [2][3][4] - Notable mentions include Longcheng Automotive Co., Ltd. and Hebei Construction Group [4][6] Group 2: Manufacturing Sector - The top 100 private manufacturing enterprises include companies like Jingye Group Co., Ltd. and Hebei Xinhua United Metallurgical Holding Group [6][7] - The manufacturing sector showcases a strong representation of steel and automotive industries [6][20] Group 3: Service Sector - The top 100 private service enterprises feature Hebei Qianxihe Food Co., Ltd. and Xinlian Logistics Group [13][14] - This indicates a growing service industry alongside traditional manufacturing [13] Group 4: R&D Investment - The top 100 private enterprises in R&D investment include Changcheng Automotive Co., Ltd. and Shijiazhuang Yiling Pharmaceutical Co., Ltd. [20][26] - This highlights the emphasis on innovation and technology development within Hebei's private sector [20] Group 5: Patent Holdings - The top 100 private enterprises for invention patents are led by Changcheng Automotive Co., Ltd. and New Hope Liuhe Co., Ltd. [26][27] - This reflects the commitment to intellectual property and innovation among leading companies in Hebei [26]

Core Viewpoint - Yiling Pharmaceutical experienced a 2.58% increase in stock price on September 9, with a trading volume of 941 million yuan, indicating positive market sentiment towards the company [1] Financing Summary - On September 9, Yiling Pharmaceutical had a financing buy-in amount of 91.5 million yuan, with a net financing buy of 8.94 million yuan after repayments [1] - The total financing and securities lending balance reached 720 million yuan, with the financing balance at 713 million yuan, accounting for 2.44% of the circulating market value, which is below the 50th percentile of the past year, indicating a low level of financing [1] - In terms of securities lending, 200 shares were repaid, and 13,800 shares were sold short, with a total selling amount of 241,100 yuan, while the securities lending balance stood at 6.8 million yuan, exceeding the 80th percentile of the past year, indicating a high level of short selling [1] Company Performance - As of June 30, Yiling Pharmaceutical had 170,100 shareholders, a decrease of 8.18% from the previous period, while the average circulating shares per person increased by 8.91% to 8,093 shares [2] - For the first half of 2025, Yiling Pharmaceutical reported a revenue of 4.04 billion yuan, a year-on-year decrease of 12.26%, while the net profit attributable to shareholders increased by 26.03% to 669 million yuan [2] - Since its A-share listing, Yiling Pharmaceutical has distributed a total of 3.954 billion yuan in dividends, with 1.337 billion yuan distributed over the past three years [2] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder with 17.5921 million shares, a decrease of 5.6782 million shares from the previous period [2] - The Southern CSI 500 ETF ranked fifth among circulating shareholders with 12.3965 million shares, an increase of 1.765 million shares [2] - The Huatai-PineBridge CSI Traditional Chinese Medicine ETF was the tenth largest circulating shareholder with 3.8498 million shares, a decrease of 432,500 shares [2]